Over 90 Total Lots Up For Auction at One Location - WA 04/08

Q&A with Jack Kolosky, Executive VP and COO of Moffitt Cancer Center

by Sean Ruck, Contributing Editor | July 06, 2018
Women's Health
From the July 2018 issue of HealthCare Business News magazine

• One of the 100 Best Places to Work in IT By Computerworld
• CEO Cancer Gold Standard reaccreditation in 2017 for the 10th year
• Named a 2017 Business of Pride and 2017 Nonprofit of the Year by the Tampa Bay Business Journal

Specialties:
Moffitt diagnoses and treats all forms of cancer, from the most common conditions, like lung, skin and breast cancer, to rarer malignancies, such as mesothelioma, throat cancer and brain cancer. They have dedicated oncologists, researchers and supportive care professionals for more than 100 unique conditions.

Moffitt's multidisciplinary approach involves
experts from many areas
Recent developments
Moffitt helped revolutionize a new immunotherapy called Chimeric Antigen Receptor T-cell therapy, or CAR T. This personalized therapy uses a patient’s own immune cells, or T cells, to fight cancer. For the treatment, T cells are removed from a patient’s blood and sent to a lab, where the cells are genetically modified to better enable them to identify and attack cancer cells. Moffitt co-led the national clinical trial that led to the approval of Yescarta™, one of the two FDA-approved CAR T therapies, and treated the first patient in the United States after approval.

Back to HCB News

You Must Be Logged In To Post A Comment